Please assess the completion status of the following clinical trial:

Trial Title: A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Is male or female ≥ 18 years of age in general good health (other than RA)~* Has an American College of Rheumatology Rheumatoid Clinical Response Criteria (ACR) Functional Class I, II, or III~* Has a diagnosis of RA at least 6 months ago and was at least 16 years of age when diagnosed~* Has a history of positive therapeutic benefit with nonsteroidal anti-inflammatory drugs (NSAIDs) and is taking an NSAID on a regular basis and at a therapeutic dose level and is not anticipated to undergo a change during the study~Exclusion Criteria:~* Has a concurrent medical/arthritic disease that could confound or interfere with evaluation of efficacy~* Has a history of gastric or biliary surgery (including gastric bypass surgery) or small intestine surgery that causes clinical malabsorption~* Has an active peptic (gastric or duodenal) ulcer or history of inflammatory bowel disease~* Has a confirmed medical diagnosis of ischemic heart disease, cerebrovascular disease, or peripheral artery occlusive disease~* Class II-IV congestive heart failure~* Has uncontrolled hypertension (systolic \>160 mm Hg or diastolic \> 90 mm Hg) at Visit 1 or Visit 2~* Has a clinical diagnosis of hepatic insufficiency defined as Child-Pugh score ≥5~* Has estimated glomerular filtration rate ≤30 mL/min~* Has a history of neoplastic disease within 5 years (exceptions: basal cell carcinoma or carcinoma in situ of the cervix)~* Is allergic to etoricoxib; history of a significant clinical or laboratory adverse experience associated with etoricoxib; hypersensitivity to aspirin or NSAIDs; or allergy to acetaminophen/paracetamol~* Has a personal or family history of an inherited or acquired bleeding disorder~* Requires oral corticosteroid therapy in excess of the equivalent of 10 mg daily of prednisone and/or have not been on a stable dose for at least 4 weeks prior to Visit 1 and/or whose dose is not expected to remain stable during the study~* Treated with B-cell depleting therapies within the past 6 months or anticipate this treatment during this trial~* Is a recreational or illicit drug use, or history within 5 years of drug or alcohol abuse/dependence;~* Is morbidly obese (defined as body mass index ≥40 kg/m\^2)~* Is pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etoricoxib 60 mg/Etoricoxib 60 mg (Type: EXPERIMENTAL): The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and Part 2 of the study.
- Etoricoxib 60 mg/Etoricoxib 90 mg (Type: EXPERIMENTAL): The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 2 of the study.
- Etoricoxib 90 mg (Type: EXPERIMENTAL): The etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
- Placebo (Type: PLACEBO_COMPARATOR): The placebo treatment sequence will receive matching placebo to etoricoxib tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).